Significant improvements in OS and RFS for older patients with AML

About 40-50% of older patients with AML attain complete remission with induction chemotherapy but the majority of them eventually relapse. At EHA 2021 Congress, Farhad Ravandi presented new data from the QUAZAR AML-001-study. It shows significant improvements in OS and RFS with CC-486, an oral hypomethylating agent. Farhad Ravandi is Professor of Medicine and Chief of Section of Developmental Therapeutics in the Department of Leukemia at the University of Texas – M. D. Anderson Cancer Center, Texas, USA.